Xiulian Miao , Yan Guo , Shanwen Gong , Jun Miao , Lingling Sun , Jing Zhuang
{"title":"Smarca4 ablation in myeloid cells attenuates non-alcoholic fatty liver disease in mice","authors":"Xiulian Miao , Yan Guo , Shanwen Gong , Jun Miao , Lingling Sun , Jing Zhuang","doi":"10.1016/j.lfs.2025.123977","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive lipid accumulation and chronic inflammation. Intercellular crosstalk between hepatocytes and macrophages contributes to NAFLD pathogenesis. We investigated how ablation of Brg1 (encoded by <em>Smarca4</em>), a component of the chromatin remodeling complex, in macrophages might influence NAFLD pathogenesis in mice.</div></div><div><h3>Methods and materials</h3><div><em>Brg1</em><sup>f/f</sup> mice were crossed to <em>LyzM</em>-Cre mice to achieve myeloid cell specific Brg1 deletion. NAFLD was induced by feeding the mice with a high-fat high-carbohydrate (HFHC) diet.</div></div><div><h3>Key findings</h3><div>Brg1 expression was up-regulated in macrophages from the mice fed the HFHC diet compared to the control diet and in peripheral blood monocytic cells from the NAFLD patients compared to the healthy individuals. Co-culture with macrophages promoted lipid accumulation in hepatocytes whereas deletion or pharmaceutical inhibition of Brg1 in macrophages disrupted macrophage-hepatocyte crosstalk. Consistently, Brg1 ablation in myeloid cells attenuated NAFLD pathogenesis in mice. Importantly, administration of a small-molecule Brg1 inhibitor PFI-3 ameliorated NAFLD in mice. RNA-seq identified C<img>C motif chemokine ligand 7 (CCL7) as a downstream target for Brg1 in macrophages.</div></div><div><h3>Significance</h3><div>Our data suggest that Brg1 might contribute to NAFLD by mediating the macrophage-hepatocyte crosstalk to pivot hepatocytes to a pro-NAFLD phenotype.</div></div>","PeriodicalId":18122,"journal":{"name":"Life sciences","volume":"381 ","pages":"Article 123977"},"PeriodicalIF":5.1000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0024320525006137","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aims
Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive lipid accumulation and chronic inflammation. Intercellular crosstalk between hepatocytes and macrophages contributes to NAFLD pathogenesis. We investigated how ablation of Brg1 (encoded by Smarca4), a component of the chromatin remodeling complex, in macrophages might influence NAFLD pathogenesis in mice.
Methods and materials
Brg1f/f mice were crossed to LyzM-Cre mice to achieve myeloid cell specific Brg1 deletion. NAFLD was induced by feeding the mice with a high-fat high-carbohydrate (HFHC) diet.
Key findings
Brg1 expression was up-regulated in macrophages from the mice fed the HFHC diet compared to the control diet and in peripheral blood monocytic cells from the NAFLD patients compared to the healthy individuals. Co-culture with macrophages promoted lipid accumulation in hepatocytes whereas deletion or pharmaceutical inhibition of Brg1 in macrophages disrupted macrophage-hepatocyte crosstalk. Consistently, Brg1 ablation in myeloid cells attenuated NAFLD pathogenesis in mice. Importantly, administration of a small-molecule Brg1 inhibitor PFI-3 ameliorated NAFLD in mice. RNA-seq identified CC motif chemokine ligand 7 (CCL7) as a downstream target for Brg1 in macrophages.
Significance
Our data suggest that Brg1 might contribute to NAFLD by mediating the macrophage-hepatocyte crosstalk to pivot hepatocytes to a pro-NAFLD phenotype.
期刊介绍:
Life Sciences is an international journal publishing articles that emphasize the molecular, cellular, and functional basis of therapy. The journal emphasizes the understanding of mechanism that is relevant to all aspects of human disease and translation to patients. All articles are rigorously reviewed.
The Journal favors publication of full-length papers where modern scientific technologies are used to explain molecular, cellular and physiological mechanisms. Articles that merely report observations are rarely accepted. Recommendations from the Declaration of Helsinki or NIH guidelines for care and use of laboratory animals must be adhered to. Articles should be written at a level accessible to readers who are non-specialists in the topic of the article themselves, but who are interested in the research. The Journal welcomes reviews on topics of wide interest to investigators in the life sciences. We particularly encourage submission of brief, focused reviews containing high-quality artwork and require the use of mechanistic summary diagrams.